1. ings in such transgenic models can offer a change in the clinical indication for a
2. valuable insights into the potential rele- drug. In such circumstances a. transgenic
3. vance and applicability of tumor findings to rodent model may be a possible alternative
4. humans that are not readily available from to repeating a 2-year carcinogenicity study.
5. standard 2-year rodent studies. Transgenic In addition the relatively short duration of